Biogen Inc.BIIB
ASignal's systematic analysis rates BIIB as Neutral. Biogen Inc. has a market cap of $29.12B, a P/E of 20.61, a 13.8% net margin, and 1.9% year-over-year revenue growth.
Reflects the latest available analysis · analyzed Jul 16, 2026
The case on BIIB
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (78.72%) indicating pricing power
- Low debt-to-equity ratio (0.35x) signaling solid financial health
- Positive free cash flow ($1.93B) supports operational efficiency
- Forward P/E of 11.92x suggests valuation discount relative to current earnings
- Weak revenue growth (1.90% YoY) indicating limited top-line expansion
- Negative price momentum (-0.0596) and bearish MACD histogram trend
- RSI near neutral (48.53), lacking strong momentum signal
- No Reddit mentions, suggesting lack of retail investor interest
Key facts
Peers
Clustered with BIIB by analysis-profile similarity.
See the full verdict on BIIB
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes BIIB
Most investors never get a second opinion, let alone several. ASignal runs BIIB past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.